Bio-Techne Corporation (NASDAQ:TECH) Q4 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Corporate Participants David Clair - Vice President, Investor Relations and Corporate Development Chuck Kummeth - Chief Executive Officer Jim Hippel - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Jacob Johnson - Stephens Dan Arias - Stifel Catherine Schulte - Baird Alex Nowak - Craig-Hallum Patrick Donnelly - Citi Paul Knight - KeyBanc Operator Good morning, and welcome to th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jur ...

Bio-Techne Corporation (NASDAQ:TECH) Q3 2022 Earnings Conference Call May 4, 2022 9:00 AM ET Company Participants David Clair - Senior Director, IR and Corporate Development Chuck Kummeth - CEO Jim Hippel - CFO Conference Call Participants Dan Arias - Stifel Puneet Souda - SVB Securities Jacob Johnson - Stephens Alex Nowak - Craig-Hallum Catherine Schulte - Baird Patrick Donnelly - Citi Paul Knight - KeyBanc Disclaimer*: This transcript is designed to be used alongside the freely available audio recording o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other ju ...

Bio-Techne Corporation (NASDAQ:TECH) Q2 2022 Earnings Conference Call February 1, 2022 9:00 AM ET Company Participants David Clair - Senior Director, IR and Corporate Development Chuck Kummeth - CEO Jim Hippel - CFO Conference Call Participants Puneet Souda - SVB Leerink Dan Arias - Stifel Jacob Johnson - Stephens Inc. Patrick Donnelly - Citi Catherine Schulte - Baird Alex Nowak - Craig-Hallum Capital Group Operator Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other ...

Bio-Techne Corporation (NASDAQ:TECH) Q1 2022 Earnings Conference Call November 2, 2021 9:00 AM ET Company Participants David Clair - Senior Director, Investor Relations and Corporate Development Chuck Kummeth - Chief Executive Officer Jim Hippel - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Dan Arias - Stifel Jacob Johnson - Stephens Alex Nowak - Craig-Hallum Catherine Schulte - Baird Patrick Donnelly - Citi Paul Knight - KeyBanc Capital Markets Operator Good morning and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the ...

Bio-Techne Corporation (NASDAQ:TECH) Q4 2021 Earnings Conference Call August 5, 2021 9:00 AM ET Company Participants David Clair - Investor Relations Chuck Kummeth - Chief Executive Officer Jim Hippel - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Jacob Johnson - Stephens Catherine Schulte - Baird Alex Nowak - Craig-Hallum Patrick Donnelly - Citi Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the Fourth Quarter of Fiscal Year 2021. [Operator Instr ...

Financial Performance - Bio-Techne reported a Q3 revenue of $243.6 million, representing a 25% year-over-year increase and a 22% organic growth [32][34] - Adjusted EPS was $1.79, a 29% increase from $1.39 in the previous year, marking a new company record [32][34] - The adjusted operating margin for the quarter was 40.1%, an increase of 360 basis points year-over-year [34][36] Business Segment Performance - The Protein Sciences segment reported sales of $185.6 million, with organic growth of 24% [39] - The Diagnostics and Genomics segment had reported sales of $58.1 million, with organic growth of 17% [40] - Simple Plex saw a 90% increase in revenue globally, driven by its application in biomarker discovery and quality control processes [17][19] Market Performance - China experienced nearly 50% growth, while EMEA grew over 30% and the Americas saw growth north of 20% [32] - The biopharma market continued to show strength with year-over-year growth well over 25% [33] - The academic sector improved significantly, growing approximately 20% for the quarter compared to last year [33] Company Strategy and Industry Competition - The acquisition of Asuragen is expected to enhance Bio-Techne's portfolio in genetic carrier screening and oncology research products [10] - The company is focusing on expanding its GMP protein capabilities and has a strong pipeline for cell and gene therapy solutions [14][16] - Bio-Techne aims to leverage its broad product offerings to create synergistic solutions for biopharma companies [16] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in sustaining high operating margins due to strong positioning in high-growth markets [9][36] - The company anticipates continued momentum in Q4, with expectations for revenue to be similar to Q3 [43] - Management noted that the COVID-19 pandemic has elevated the profile of their tools and solutions, positioning the company for stronger growth post-pandemic [28] Other Important Information - The company generated $74.9 million in cash from operations, a more than 50% increase over the prior year [37] - Bio-Techne's balance sheet remains strong with $276.2 million in cash and short-term investments and essentially zero net debt [38] - The company is expanding its manufacturing capacity to meet the high demand for its Simple Plex solution [19] Q&A Session Summary Question: Can you discuss the early days of servicing customers with expanded GMP capabilities? - Management indicated that the catalog is not a limitation, and they are making progress with several customers, expecting to meet their needs effectively [48] Question: How sustainable is the strong operating margin? - Management expressed confidence in sustaining the operating margin, noting that they are ahead of their previous guidance and expect continued strong performance [56][59] Question: What is the size of the end market for cell and gene therapy? - Management estimated the current run rate across the portfolio at about $50 million, with potential to grow to over $500 million in the next five years [74]